Gliknik Inc., a Baltimore, MD-based immunology company dedicated to patients with cancer and autoimmune disorders, completed an $11.5m Series C financing.
The round was led by First In Ventures (FIV) with participation from SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings. Kyle Rusconi, a founder of FIV, is joining the Gliknik Board.
Led by CEO David Block, Gliknik is an immunology company creating and advancing biologic drugs for patients with cancer and autoimmune disorders. The company, which has secured $81m to date, intends to use the funds to progress the pipeline of its product candidates, including:
- A randomized double-blind, placebo-controlled phase 2 study of Gliknik immuno-oncology compound biropepimut-S, which is nearing completion,
- Gliknik immune modulating compound GL-2045, a recombinant mimetic of pooled human IVIG, which is a potent clinical candidate under active development by Gliknik licensee Pfizer for autoimmune diseases.
- GL-0719 is a new type of complement modulator, which is designed to control diseases while leaving critical host defense systems intact. GL-0719 is poised to enter a phase 1 trial in 2021.
- Other compounds in preclinical development